Skip to content
Global Health logo

Global Health

MEDANTA NSE
₹1,480.20 +1.90 (+0.13%)
Market Cap
₹39,798 Cr
P/E
64.33
View as Markdown
MCP
Close 20 Nov 2026 ₹1,480.20 1Y +229.70 +18.4%
Start ₹1,250.50

Key Fundamentals

MidcapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
17.40%
Debt to Equity
0.31
EPS (TTM)
₹23.01
Book Value
₹160.82
Market Cap
₹39,798 Cr
P/E (TTM)
64.33
P/B
9.20
ROE
15.20%
Dividend Yield
0.03%
EBITDA
₹1,018 Cr
52W High
₹1,544.00
52W Low
₹956.00
Day Range
₹1,472.20 – ₹1,509.30
Volume
2,65,365

Peer Comparison

Healthcare › Healthcare Services › Hospital

Global Health peer comparison
9,200.0059.001,32,28212.470.23%21.50%17.40%27,6302,337
1,081.0076.231,05,2159.280.20%14.70%14.70%9,1461,380
702.20101.7792,3666.010.00%6.72%8.30%12,370873
779.30110.7067,9298.720.41%11.30%11.60%6,508564
825.0059.9662,2845.940.13%11.20%13.40%9,9101,061
Global Health (this company)
1,480.2064.3339,7989.200.03%15.20%17.40%5,053613
1,943.7046.2539,7227.940.24%20.50%15.50%10,273859
Median 7 companies1,081.0064.3367,9298.720.20%14.70%14.70%9,910873

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

45 Average

Data confidence 100/100

Category scores

Quality
39
Weak
Returns, margins, earnings quality 22% weight
Valuation
31
Poor
Cheap vs sector & own history 24% weight
Growth
79
Strong
Sales & profit trajectory 9% weight
Financial Health
52
Average
Solvency, leverage, coverage 9% weight
Momentum
45
Average
Trend strength, vol-adjusted 12% weight
Ownership
54
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has delivered good profit growth of 80.7% CAGR over last 5 years

Weaknesses

1
  • Stock is trading at 9.21 times its book value

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish3313
OscillatorsNeutral333
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
68.37
Neutral
MACD (12,26,9)
38.53
Bullish
SMA (50)
1,370.05
Bullish
SMA (200)
1,267.08
Bullish

As of

Analyst Rating

Based on 16 analysts
BUY94%

15 of 16 analysts rate Buy, 1 Hold, 0 Sell.

As of

BUY
15
94%
HOLD
1
6%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+12.30%
5Y+24.97%
3Y+17.62%
1Y+19.45%
TTM+26.20%

Net profit

Net profit growth by window
10Y+12.54%
5Y+80.39%
3Y+19.33%
1Y+15.18%
TTM+9.27%

Operating cash flow

Operating cash flow growth by window
10Y+12.09%
5Y+24.16%
3Y+3.45%
1Y+14.42%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−0.69 pp
5Y+7.48 pp
3Y−2.42 pp
1Y−2.91 pp
TTM−1.37 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2016₹1,382 Cr
Mar 2018₹1,343 Cr
Mar 2019₹1,456 Cr
Mar 2020₹1,500 Cr
Mar 2021₹1,447 Cr
Mar 2022₹2,167 Cr
Mar 2023₹2,710 Cr
Mar 2024₹3,275 Cr
Mar 2025₹3,692 Cr
Mar 2026₹4,410 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2016₹170 Cr
Mar 2018₹33.00 Cr
Mar 2019₹51.00 Cr
Mar 2020₹36.00 Cr
Mar 2021₹29.00 Cr
Mar 2022₹196 Cr
Mar 2023₹326 Cr
Mar 2024₹478 Cr
Mar 2025₹481 Cr
Mar 2026₹554 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹311 Cr −21.1% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 17 Nov 2026
AI opinion · based on fundamentals
Risk high

Global Health Ltd (Medanta) trades at ₹1,444.2 as of 2026-11-17 with a market cap of ₹38,830 crore and a P/E of 62.76x. The company has delivered strong profit growth of roughly 81% CAGR over five years and maintains a low debt-to-equity ratio of 0.30, but its valuation at 8.98x book value and a TTM P/E north of 60x place it at a significant premium to broader market averages.

Bull Case 7
  • Exceptional 5-year compounded profit growth of 81%, reflecting a strong earnings trajectory as hospital operations scaled up
  • Robust 5-year compounded sales growth of 25%, with TTM sales growth accelerating further to 26%, indicating sustained demand momentum
  • Conservative balance sheet with a debt-to-equity ratio of just 0.30, providing financial flexibility for expansion without heavy leverage
  • ROCE of 15.05% suggests efficient deployment of capital across hospital assets, a positive sign for a capital-intensive healthcare business
  • 3-year stock CAGR of 17% and 1-year stock CAGR of 21% show the market has consistently rewarded the company's operational performance
  • 3-year compounded profit growth of 19% and 3-year compounded sales growth of 18% demonstrate that growth has continued beyond a one-time post-pandemic recovery
  • ROE has been consistently around 15-16% over the last three and five years, indicating steady return generation for shareholders despite rapid expansion
Bear Case 6
  • Trading at a P/E of 62.76x on a TTM basis, which is well above typical large-cap healthcare peers and leaves little room for earnings disappointment
  • Price-to-book ratio of 8.98x is elevated, meaning the stock prices in substantial future growth that must be delivered to justify the premium
  • TTM profit growth has decelerated to 11% from the 3-year CAGR of 19%, raising questions about whether the high-growth phase is moderating
  • Dividend yield of just 0.03% offers virtually no income return, making the stock entirely dependent on capital appreciation
  • ROE of 13.91% (current) is modest relative to the lofty valuation multiples; a P/B of nearly 9x typically demands meaningfully higher return on equity
  • 10-year compounded profit growth of 13% and 10-year sales growth of 12% show that the longer-term base rate of growth is far more moderate than recent 5-year figures suggest

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

22h ago

TL;DR: Global Health delivered a strong Q2FY27 with 38% profit growth and margin expansion to 25.2%, signalling robust operational momentum. However, back-to-back senior exits — the Gurugram Hospital Director leaving to a competitor and the HR head resigning — flag potential leadership churn risk. The scheduled analyst meetings may provide further clarity on growth trajectory and management stability. The earnings trend is positive, but retention of key talent at flagship units bears watching.

Headwinds 1
  • Hospital Director exits to competitor Oct 31

    Dr. Pankaj Dhamija, Hospital Director at Medanta Gurugram, resigned effective October 30, 2026, with departure accelerated due to planned competition — a potential talent and operational continuity risk at a flagship unit.

Positives 1
  • Q2 PAT up 38%, margins expand Nov 3

    Global Health reported Q2FY27 net profit of ₹2,191 million, up 38.3% YoY. Operating EBITDA margin expanded to 25.2%, driven by strong volume growth.

Neutral 2
  • Analyst meetings scheduled Nov 16-17 Nov 10

    Global Health will hold one-to-one meetings with nine institutional investors and analysts on November 16-17, 2026, in person.

  • HR head resigns, ESOPs granted Nov 2

    SVP & Head-HR Saurabh Upadhyay resigned effective December 23, 2026. The company also granted 3.14 lakh ESOPs at ₹635 per share.

Quarterly Results

₹ Cr
MEDANTA quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
844
836
809
861
957
943
931
1,031
1,099
1,121
1,159
1,304
1,469
Expenses
631
620
629
675
728
706
707
784
868
904
915
1,017
1,099
Operating Profit
213
216
179
186
228
238
225
247
231
217
244
287
370
OPM %
25%
26%
22%
22%
24%
25%
24%
24%
21%
19%
21%
22%
25%
Other Income
21
18
27
22
18
16
22.93
20
19.73
21.78
37
22
23.62
Interest
20
18
18
18
16
16
15
14
17
22
27
27
28.09
Depreciation
43
44
45
47
49
48
49
45
50
61
67
69
70.8
Exceptional Items
—
—
—
—
—
—
−49.9
—
15.99
−36.6
—
—
—
PBT
171
172
143
144
181
189
133
208
200
120
187
213
295
Tax %
27%
28%
11%
26%
28%
24%
24%
24%
21%
21%
24%
26%
26%
Net Profit
125
124
127
106
131
143
101
159
158
95
142
157
219
EPS (₹)
4.66
4.61
4.74
3.96
4.87
5.32
3.78
5.92
5.89
3.54
5.36
5.90
8.21
YoY Sales growth
24
20
14
10
13
13
15
20
15
19
24
26
34

Profit & Loss

₹ Cr
MEDANTA profit and loss, annual, ₹ crore
Particulars Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,382
1,343
1,456
1,500
1,447
2,167
2,710
3,275
3,692
4,410
5,053
Expenses
1,081
1,218
1,283
1,309
1,250
1,709
2,073
2,466
2,806
3,480
3,935
Operating Profit
301
125
172
192
197
458
637
809
886
930
1,118
OPM %
22%
9%
12%
13%
14%
21%
24%
25%
24%
21%
22%
Other Income
45
49
50
44
31
39
49
75
79.1
98.59
68
Interest
14
28
38
57
73
86
86
84
74
90
103
Depreciation
70
86
102
115
123
130
150
173
194
223
267
Exceptional Items
—
—
—
—
—
—
—
—
−49.9
—
—
PBT
262
60
83
64
32
281
449
627
647
715
815
Tax %
35%
45%
38%
43%
11%
30%
27%
24%
26%
23%
—
Net Profit
170
33
51
36
29
196
326
478
481
554
613
EPS (₹)
6.72
1.30
2.03
1.43
1.14
7.75
12.16
17.81
17.92
20.70
23.01
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
2%
—
Sales growth
—
—
8
3
−4
50
25
21
13
19
26

Balance Sheet

₹ Cr
MEDANTA balance sheet, annual, ₹ crore
Particulars Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
48
48
49
49
50
51
54
54
54
54
54
Reserves
976
1,136
1,246
1,300
1,333
1,565
2,375
2,852
3,333
3,908
4,270
Borrowings
165
456
787
929
931
1,109
1,122
802
718
1,190
1,353
Other Liabilities
295
343
347
388
380
421
547
572
662
753
930
Total Liabilities
1,485
1,984
2,430
2,666
2,694
3,146
4,097
4,280
4,766
5,905
6,606
Fixed Assets
914
1,094
1,194
1,703
1,616
1,776
2,050
2,236
2,514
3,795
3,957
CWIP
12
317
666
382
464
439
327
388
533
132
207
Investments
0
0
0
0
0
0
0
0
3
3
3
Other Assets
559
573
570
581
615
930
1,720
1,656
1,716
1,975
2,440
Total Assets
1,485
1,984
2,430
2,666
2,694
3,146
4,097
4,280
4,766
5,905
6,606

Cash Flow

₹ Cr
MEDANTA cash flow, annual, ₹ crore
Particulars Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
228
63
166
175
242
311
645
612
624
714
Investing
−241
−69
−249
−87
−239
−421
−342
−441
−721
−1,089
Financing
−7
9
97
−1
−81
160
346
−514
−97
272
Net Cash Flow
−20
3
14
87
−78
50
648
−343
−194
−103
Free Cash Flow
71
−81
−133
−13
100
38
409
335
110
−123
CFO/EBITDA
108
93
135
121
131
89
118
98
89
90

Ratios

MEDANTA financial ratios, annual
Particulars Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
20
41
41
36
34
30
26
24
29
34
Inventory Days
28
26
26
43
42
36
35
32
28
29
Days Payable
92
124
142
147
138
90
114
90
81
89
Cash Conversion Cycle
−45
−56
−75
−67
−62
−24
−52
−34
−24
−26
Working Capital Days
−23
−33
−18
−31
−48
−20
−37
−32
−21
−7
ROCE %
—
—
6%
6%
5%
15%
17%
20%
20%
17%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Global Health insights

65 extracted metrics across FY16–FY27.

Shareholding Pattern

As of Sep 2026

  • Others 34.68%
  • Promoters 33.00%
  • DIIs 17.01%
  • FIIs 9.91%
  • Public 5.40%

No promoter shares pledged as of 14 Oct 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Global Health

What does Global Health Ltd do?
Global Health Limited operates a network of multi-specialty tertiary and quaternary care hospitals under the Medanta brand, primarily across North and East India.
Where is Global Health Ltd (MEDANTA) listed?
Global Health Ltd trades as MEDANTA on the NSE and under code 543654 on the BSE.
Which sector does Global Health Ltd belong to?
Global Health Ltd is classified under the Healthcare sector, in the Healthcare Services industry.
What is the market capitalisation of Global Health Ltd?
Global Health Ltd has a market capitalisation of ₹39,798 Cr as of 20 Nov 2026, which places it in the Midcap band.
What is the PE ratio of Global Health Ltd?
Global Health Ltd trades at a PE ratio of 64.33 as of 20 Nov 2026, on earnings per share of ₹23.01, against a book value of ₹160.82 per share.
What is the 52-week high and low of Global Health Ltd?
Over the last 52 weeks Global Health Ltd has traded between ₹956 and ₹1,544 as of 20 Nov 2026.
Does Global Health Ltd pay dividends?
Global Health Ltd has a dividend yield of 0.03%.
What is the Return on Equity (ROE) of Global Health Ltd?
Global Health Ltd reported a return on equity of 15.20%. Its debt-to-equity ratio is 0.31.

Company Information

Global Health Limited operates a network of multi-specialty tertiary and quaternary care hospitals under the Medanta brand, primarily across North and East India. The company specialises in cardiac sciences, oncology, neurosciences, digestive and hepatobiliary sciences, orthopaedics, organ transplantation, kidney and urology, and other complex medical procedures. As of June 2026, Medanta operated six hospitals across Gurugram, Lucknow, Patna, Ranchi, Indore and Noida, supported by an expanding diagnostics, pharmacy and outpatient network.

Website medanta.org
Listed 16 Nov 2022
Face Value ₹2
Shares Outstanding 26,88,71,782

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MEDANTA.md for Global Health Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More